Day 1: 20 September 2021
| 10:00 (CET) |
| Overcoming Tumor Antigen Heterogeneity in the Context of CAR T Cell therapy for Solid Tumors Astero Klampatsa Thoracic Oncology Immunotherapy Group, The Institute of Cancer Research, Division of Cancer Therapeutics, London, UK |
| 11:00 |
Tumor Endothelial Cells in NSCLC: headmasters of tumor immunity Andreas Pircher Department of Internal Medicine V (Hematology and Oncology) Medizinische Universität Innsbruck, Innsbruck, Austria |
| 13:00 |
| Modeling Therapy-Induced Tumor Cell State Plasticity to Identify Vulnerabilities for Reducing Disease Burden Jonathan A. Kelber Department of Biology, California State University Northridge (CSUN), Los Angeles, California |
| 14:00 |
| Glucocorticoids and Angiogenesis Julie Goodwin Yale School of Medicine, New Haven, CT, USA |
| 15:00 |
| Cracking open the undruggable RAS: A Clinical Perspective David S.Hong Associate Vice President of Clinical Research, University of Texas M.D. Anderson Cancer Center, Deputy Chair of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, Houston, USA. |
| 16:00 |
| Identification of distinct immune signatures in malignant pleural mesothelioma Cara Haymaker Director, Oncology Research and Immuno-monitoring Core (ORION) Director, Translational Molecular Pathology and Immunoprofiling Lab, UT MD Anderson Cancer Center, Houston, TX, US |
| 17:00 |
| Development of a novel biodegradable chemo-radioembolic formulation for transarterial treatment of hepatocellular carcinoma (Poster Talk) Asseel AlregibSchool of Medicine, Taylor’s University, Subang Jaya, Malaysia |
| Day End |
Day 2: 21 September 2021
| 10:00 (CET) |
| Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs Armando Bartolazzi Department of Pathology, Sant’Andrea University Hospital, Rome, Italy |
| 11:00 |
| Role of calcineurin in affecting tumor growth and the formation of the tumor microenvironment Francesca Granucci Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy |
| 13:00 |
| Unleashing the potential of liquid biopsy in solid tumors: diagnosis, recurrence and resistance Marzia Del Re Unit of Clinical Pharmacology and Pharmacogenetics, Dipartimento di Medicina Clinica e Sperimentale, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy |
| 14:00 |
| Combination of integrated genomics with ex vivo microcancer drug screens to individualize brain cancer therapy Panos Z. Anastasiadis Cell Biology Program Director, Cell Adhesion and Metastasis Laboratory Mayo Clinic Cancer Center, Jacksonville, FL, USA |
| 15:00 |
| Age of combination therapy in the treatment of advanced RCC: can we do it better? Che-Kai Tsao Medical Director, Ruttenberg Treatment Center, Tisch Cancer Institute, Mount Sinai Hospital, NY, USA |
| 16:00 |
| Proteomic and N-glycome profiling of secretome from BRAFV600E mutant colon cancer cells with acquired resistance to vemurafenib (Poster Talk) Iris Car University of Rijeka, Department of Biotechnology, Rijeka, Croatia |
| 17:00 |
| Identifying emerging novel metastatic castration-resistant prostate cancer therapies; understanding PARPi in combination with AR-targeted treatments | satellite symposium Pedro Barata, Jorge A. Garcia and Elisabeth Heath *Tulane Medical School Department of Internal Medicine, New Orleans, Louisiana,USA., *Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA. and *Karmanos Cancer Institute, Wayne State School of Medicine, Detroit, Michigan |
| Day End |
Day 3: 22 September 2021
| 10:00 (CET) |
| Investigating protein- and gene-expression of 27 cytokines/chemokines in melanoma patients. Identification of a 4-genes signature Antonio Facchiano Istituto Dermopatico dell’Immacolata (IDI-IRCCS), Rome, Italy |
| 11:00 (CET) |
| MET as a druggable target in solid tumors Qian Xie Department of BioMedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, US |
| 13:00 |
| Molecular Testing and Liquid Biopsy for Ovarian Cancer Jianyu Rao UCLA Medical Center, Santa Monica, LA, USA |
| 14:00 |
| Flexible samarium-153 radiotherapeutic bandage for radiation therapy of skin cancer Wong Yin How School of Medicine, Faculty of Health & Medical Sciences, Taylor’s University, Subang Jaya, Malaysia |
| 15:00 |
| Ion channel drugs as electroceuticals for reprogramming cancer: exploiting bioelectric controls of cell and tissue function Michael Levin Tufts University, Medford, USA |
| 16:00 |
| Identification of Novel Biomarkers of Response to Irinotecan in Patients with Colorectal Cancer (Poster Talk) Jing LiUniversitat Autònoma de Barcelona, Barcelona, Spain |
Day 4: 23 September 2021
| 10:00 (CET) |
| Potential prostate cancer targeting strategies revealed by integrative proteogenomics Leena Latonen School of Medicine, Institute of Biomedicine, University of Eastern Finland Kuopio, Finland |
| 11:00 |
| Two retrospective studies on gender differences: chemotherapy toxicities in patients affected by colorectal and pancreatic cancers Silvia De Francia Department of Clinical and Biological Sciences, University of Turin, Orbassano (TO), Italy |
| 13:00 |
| Mesenchymal stem/stromal cells and the tumor tissue microenvironment Yufang Shi Soochow University Institutes for Translational Medicine & Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China |
| 14:00 |
| Vitiligo and vitiligo-associated markers as indicators of response to immunological checkpoint inhibitors in cutaneous melanoma Cristina M. Failla Experimental Immunology Laboratory, IDI-IRCCS, Rome, Italy |
| 15:00 |
| Targeting glycosaminoglycans in solid tumors Mads Daugaard Molecular Pathology & Cell Imaging Core Facility, Vancouver Prostate Centre Department of Urologic Sciences, University of British Columbia, Vancouver, Canada |
| 16:00 |
| Designing a Multi-Epitope Vaccine Against Cancer-Testis Antigens in Non-Small Cell Lung Cancer: an In Silico Approach (Poster Talk) Leana Rich M. HerreraPolytechnic University of the Philippines, Philippines |
| 17:00 |
| Role of maintenance immunotherapy in metastatic urothelial carcinoma; which patients are eligible? | satellite symposium Shilpa Gupta, Vadim Koshkin and Jorge A. Garcia *Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, *Division of Hematology and Oncology, University of California San Francisco and *Oncology University Hospitals Seidman Cancer Center, Cleveland, OH, USA |
| Day End |
Day 5: 24 September, 202110:00 (CET) |
| Advanced ovarian cancer: exploiting exosomes to potentiate the anti-cancer immune response Bruna Corradetti Houston Methodist Research Institute, Houston, USA & School of Medicine at Swansea University, Wales, UK |
| 11:00 |
| A phase I study of Affinity-tuned ICAM-1 specific CAR T against advanced thyroid cancer patients Moonsoo M. Jin Director, Molecular Imaging Innovations Institute (MI3), Department of Radiology, Weill Cornell Medicine, New York, USA |
| 13:00 |
| Imaging of tumor acidosis for monitoring response to novel anticancer therapies Dario Longo Institute of Biostructures and Bioimaging (IBB), Italian National Research Council (CNR) Torino, Italy |
| 14:00 |
| Tensor-Decomposition-Based Unsupervised Feature Extraction Applied to Prostate Cancer Multiomics Data Y-h. Taguchi Department of Physics, Chuo University, Tokyo, Japan |
| 15:00 |
| The Third Dimension in Prostate Cancer Francisco La Rosa University of Colorado, AMC Department of Pathology, Aurora, CO, US |
| 17:00 |
| Solid Tumors: Immuno-Oncology Disis, Mary L. (Nora) Director, Cancer Vaccine Institute, University of Washington (UW) Director, Institute of Translational Health Sciences UW, Seattle, WA, USA |
| Day End |
Day 6: 25 September, 2021 |
| 10:00 (CET) |
| The Role of LIN28B Oncogene in Regulating Migration & Invasion of Neuroblastoma Cells Sanja Aveic Fondazione Istituto di Ricerca Pediatrica Città della Speranza, Padua, Italy RWTH Aachen University Hospital, Dental Materials and Biomaterials Research, Aachen, Germany |
| 11:00 |
| The role of General Practitioners in Cancer Control. An underexploited resource in translational oncology Pier Giorgio Natali Ex. Scientific Director, Regina Elena Institute (IRE), Rome, Italy |
| 14:00 |
| Prognostic factors on her2-positive metastatic breast cancer patients treated with trastuzumab emtansine – real-world study (Poster Talk) Maria João SousaOncology Institute of Coimbra, Coimbra, Portugal |
| 15:00 |
| Mutation-Selection Balance and Compensatory Mechanisms in Tumor Evolution Eugene V Koonin National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, USA |
| 17:00 |
| Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice | satellite symposium Ehab Atallah, Giuseppe Saglio and Kendra Sweet *Section Head, hematological malignancies, Medical College of Wisconsin, Milwaukee, WI, USA, *Division of Internal Medicine and Haematology, University of Turin, Turin, Italy and *Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa, FL, USA |
| Day End |
Day 7: 26 September, 202110:00 (CET) |
| The Role of p63 in the Female Germline Fidelity and Related Cancers Gerry Melino Faculty of Medicine, University of Rome – Tor Vergata, Rome, Italy |
| 11:00 |
The common soil hypothesis for Cancer and Cardiovascular disease: evidence from experimental and epidemiological studies Licia Iacoviello IRCCS Neuromed, Pozzilli & University of Insubria Varese, Italy |
| 13:00 |
| Apocrine breast carcinoma from biomarkers to therapy Zoran Gatalica Director of Anatomic Pathology, University of Oklahoma Health Sciences Center, Oklahoma, USA. |
| 14:00 |
| The Evolution of Precision Medicine- Entering the Era of Multi-omics John L. Marshall Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital Director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Washington DC, USA |
| 15:00 |
A lncRNA signature associated with tumour immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma (Poster Talk) Ye-Lin Liang Sun Yat-sen University Cancer center, Guangzhou, China |
| 16:00 |
Associating Transcriptomics Data with Inflammatory Markers to Understand Tumour Microenvironment in Hepatocellular Carcinoma (Poster Talk) Basak Bahcivanci College of Medical & Dental Sciences, University of Birmingham, Birmingham , UK |
| Congress End |
★ Agenda is being updated regularly
